Concarlo Therapeutics
An exciting new biotech startup developing novel therapeutics to target ER/PR+ Her2- breast cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | $2.6m | Grant | |
| Total Funding | 000k | ||
Related Content
Concarlo Therapeutics is a biotechnology company focused on developing innovative therapies to treat drug-resistant cancers. The company leverages cutting-edge research in p27 biology to create novel therapeutics aimed at dramatically improving patient outcomes. Concarlo operates in the oncology market, primarily serving cancer patients who have not responded to existing treatments. The business model revolves around the development and commercialization of proprietary drugs, which generate revenue through sales, partnerships, and licensing agreements. By targeting the CDK pathway, Concarlo aims to make cancer a treatable, manageable, and survivable condition.
Keywords: biotechnology, oncology, drug-resistant, cancer, p27 biology, CDK pathway, therapeutics, innovation, patient outcomes, commercialization.